{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:selexipag",
  "owner": "cardio",
  "kind": "drug",
  "slug": "selexipag",
  "name": "Selexipag",
  "aliases": [
    "UPTRAVI"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Selexipag, sold as Uptravi, is a prostacyclin receptor agonist. The US label lists treating pulmonary arterial hypertension (PAH, WHO Group I): in adults, to delay disease progression and lower the risk of hospital admission for PAH, and, separately, in pediatric patients aged two years and older, where the label says it reduces NT-proBNP and is expected to delay disease progression and lower the risk of hospital admission for PAH. The label says the medicine acts as an agonist at the prostacyclin receptor and is structurally distinct from prostacyclin.",
  "summary_technical": "RxNorm ingredient 1729002; UNII 5EXC0E384L. MeSH has no descriptor for selexipag (name lookups on 2026-11-18 found only a supplementary concept term), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class Prostacyclin Receptor Agonist, so the record is filed under the prostacyclin pathway page. The label read is the Actelion Pharmaceuticals US, Inc. label for Uptravi, applications NDA207947 and NDA214275, effective 2026-05-28 in openFDA. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "1729002",
      "normalized_value": "1729002",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "5EXC0E384L",
      "normalized_value": "5EXC0E384L",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin."
  },
  "content_digest": "540800dee242798c7b82bf40066d44f36c89bcab18746ed3e9dcdeaee5ae1385",
  "review": {
    "content_digest": "540800dee242798c7b82bf40066d44f36c89bcab18746ed3e9dcdeaee5ae1385",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-uptravi-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:selexipag",
      "category": "descriptive",
      "statement": "The US label of Uptravi (selexipag, Actelion Pharmaceuticals US, Inc., applications NDA207947 and NDA214275; the version dated 2026-05-28 in openFDA) describes selexipag as a prostacyclin receptor agonist. It lists treating pulmonary arterial hypertension (PAH, WHO Group I) in adults to delay disease progression and lower the risk of hospital admission for PAH.",
      "context": {
        "id": "cardio:ctx-fda-uptravi-label-us",
        "label": "Adults with pulmonary arterial hypertension, as described in the US label of Uptravi",
        "recipient": "adult",
        "population": "Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA207947.",
          "snapshot": {
            "id": "cardio:openfda-label-uptravi-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:39Z",
            "content_hash": "7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041",
            "source_effective_date": "2026-05-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-uptravi",
            "source_type": "regulator",
            "title": "openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-uptravi.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260528.",
          "snapshot": {
            "id": "cardio:openfda-label-uptravi-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:39Z",
            "content_hash": "7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041",
            "source_effective_date": "2026-05-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-uptravi",
            "source_type": "regulator",
            "title": "openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-uptravi.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-SEL-LB-04, Q-K30-SEL-LB-05).",
          "snapshot": {
            "id": "cardio:openfda-label-uptravi-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:39Z",
            "content_hash": "7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041",
            "source_effective_date": "2026-05-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-uptravi",
            "source_type": "regulator",
            "title": "openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-uptravi.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "675906d02eaf6a1fd2d7d89d3afd32c8b634dc4506bd1428f75e23527a9bb7a0",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-uptravi-label-indications.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-uptravi-label-paediatric",
      "owner": "cardio",
      "subject_entity_id": "cardio:selexipag",
      "category": "descriptive",
      "statement": "The same US label of Uptravi separately lists treating pulmonary arterial hypertension (PAH, WHO Group I) in pediatric patients aged two years and older. The label says Uptravi reduces NT-proBNP and is expected to delay disease progression and lower the risk of hospital admission for PAH.",
      "context": {
        "id": "cardio:ctx-fda-uptravi-label-paediatric",
        "label": "Pediatric patients aged 2 years and older with pulmonary arterial hypertension, as described in the US label of Uptravi",
        "recipient": "child",
        "population": "Pediatric patients aged two years and older with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Pediatric patients aged two years and older, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Pediatric patients aged two years and older with pulmonary arterial hypertension (PAH, WHO Group I), as the label states."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "The label words the pediatric benefit as expected, and this claim keeps that wording. It is not a finding about how well the medicine works in children. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA207947.",
          "snapshot": {
            "id": "cardio:openfda-label-uptravi-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:39Z",
            "content_hash": "7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041",
            "source_effective_date": "2026-05-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-uptravi",
            "source_type": "regulator",
            "title": "openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-uptravi.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260528.",
          "snapshot": {
            "id": "cardio:openfda-label-uptravi-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:39Z",
            "content_hash": "7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041",
            "source_effective_date": "2026-05-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-uptravi",
            "source_type": "regulator",
            "title": "openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-uptravi.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K30-SEL-LB-06, Q-K30-SEL-LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-uptravi-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:39Z",
            "content_hash": "7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041",
            "source_effective_date": "2026-05-28",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-uptravi",
            "source_type": "regulator",
            "title": "openFDA drug label record for Uptravi (selexipag tablets and titration pack), Actelion Pharmaceuticals US, Inc. label: indication wording and mechanism (class page)",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%22a7a23b87-f892-4e2c-8e2e-ebf841220f90%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id a7a23b87-f892-4e2c-8e2e-ebf841220f90 (manufacturer Actelion Pharmaceuticals US, Inc., application NDA207947 and NDA214275), returned on 2026-11-18. The label text is dated 2026-05-28 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-uptravi.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "b121ea3774436e802d3344134c9b3cdeaed03a0b028e163f753c2525f7c3dfb0",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-uptravi-label-paediatric.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Selexipag is a prostacyclin receptor agonist (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:prostacyclin-pathway-drugs",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-1729002-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists pulmonary arterial hypertension (WHO Group I) in adults, to delay disease progression and lower the risk of hospital admission for PAH, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-uptravi-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label separately lists pulmonary arterial hypertension in pediatric patients aged two years and older as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-uptravi-label-paediatric",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/selexipag/",
  "context_path": "api/v1/context/cardio--selexipag.md"
}
